OCTAPHARMA
Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to the NuPreviq Approach. Data from the NuPreviq study (GENA-21, NCT01863758) were published online in April 2017 as an Early View article in the internationally renowned medical journal, Haemophilia .
The NuPreviq study was initiated in August 2013 with the aim of developing a fully personalized service for HA patients undergoing prophylactic therapy. Octapharma’s aim is to improve patient treatment experiences by recognizing that no two HA patients are the same, therefore a “one size fits all ” approach to prophylaxis is not ideal. The NuPreviq study investigated a novel approach, allowing the Nuwiq® treatment regimen to be adapted to the specific needs of each individual patient. The NuPreviq Approach measures and profiles each individual patient’s pharmacokinetic response to treatment, which then allows the dosing of Nuwiq® to be personalized according to the specific circumstances of that patient.
The results of the study showed that this personalized prophylaxis approach was very effective at preventing bleeds, while reducing the frequency of dosing and the amount of Nuwiq® needed. Over 80% of patients did not experience a spontaneous bleed during the 6 months of personalized prophylaxis with Nuwiq® . More than half of the patients received infusions twice a week or less, and dose requirements were reduced by 7%. An ongoing extension study (GENA-21b, NCT02256917) will further evaluate the long-term efficacy and safety of personalized prophylaxis with Nuwiq® .
Larisa Belyanskaya, Head of IBU Haematology at Octapharma, said: “We are very excited by the results of the NuPreviq study and pleased that the GENA-21 study data are now available to the wider public in the specialist peer-reviewed publication, Haemophilia. The study shows that personalized prophylaxis with Nuwiq ® provides excellent bleeding protection, extension of the dosing interval for most patients, and a reduction in dose. These data further differentiate Nuwiq ® from other products on the market.”
Olaf Walter, Board Member at Octapharma, commented that “Octapharma’s principal motivation lies with providing dedicated service to our patients. Developing a custom care package which offers flexible FVIII therapy , truly personalized to suit their needs and lifestyle, has long been a goal of the company and we celebrate today this landmark publication of the extremely positive NuPreviq clinical data.”
Octapharma would like to thank everyone involved in the study, in particular the patients and their families, without whom this research would not be possible.
About GENA-21 and GENA-21b studies: The GENA-21 and GENA-21b studies, initiated in August 2013 and March 2015, respectively, are prospective, open-label, multicentre, Phase 3b studies assessing the safety and efficacy of PK-guided personalized prophylaxis with Nuwiq® in previously treated adult patients with severe HA. The studies are each conducted across 29 study locations worldwide.
About Nuwiq ® : Nuwiq® is a naturally long-acting, 4th generation rFVIII protein, produced in a human cell line without chemical modification or fusion with any other protein. Nuwiq® is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 PTPs (190 individuals) with severe HA, including 59 children. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned.
About haemophilia A: Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralizing FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%.
About Octapharma :
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.
In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care
Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.
For more information visit www.octapharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005497/en/
Contact:
Octapharma AG
International Business Unit - Haematology
Olaf
Walter
Olaf.Walter@octapharma.com
or
Larisa
Belyanskaya
Larisa.Belyanskaya@octapharma.com
Tel:
+41 55 4512121
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Pushes Capacitor Design with World’s First 10µF/50Vdc MLCC in 0805-inch Size for Automotive Applications26.6.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced the new GCM21BE71H106KE02 multilayer ceramic capacitor (MLCC) has entered mass production. The device is the world's first 0805-inch size (2.0 x 1.25 mm) MLCC to offer a capacitance of 10µF with a 50Vdc rating and is specifically engineered for automotive applications*. This cutting-edge product marks a significant advancement in MLCC design, delivering a smaller 0805-inch package while maintaining capacitance, voltage rating, and MLCC reliability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250611043543/en/ [Murata Manufacturing Co., Ltd.] 10µF/50Vdc MLCC in 0805-inch Size for Automotive Applications Advancements in advanced driver-assistance systems (ADAS) and autonomous driving (AD) technologies necessitate deploying an increased number of integrated circuits (ICs) within vehicle systems. This surge in ICs simultaneously leads to a greater
Mars’ Pending Acquisition of Kellanova Clears FTC Antitrust Review26.6.2025 02:07:00 CEST | Press release
Mars, Incorporated, a family-owned, global leader in pet care, snacking and food, and Kellanova (NYSE: K), a leader in global snacking, international cereal and noodles and North America frozen foods, today announced that the U.S. Federal Trade Commission (FTC) has concluded its antitrust review of Mars’ pending acquisition of Kellanova. Poul Weihrauch,CEO & Office of the President, Mars, Incorporated, said: “We are very pleased that the FTC has completed its review of the transaction without the imposition of any condition or requiring any remedy. The transaction has now received all but one of the 28 required regulatory clearances, with only the review by the European Commission outstanding. This brings us one step closer to uniting two iconic businesses with complementary footprints and portfolios, allowing us to deliver more choice and innovation to consumers.” Steve Cahillane, Chairman, President & CEO, Kellanova, said: “This represents a significant milestone on our path to combi
VeriSilicon Expands DSP Portfolio with Silicon-Proven ZSP5000 Vision Core Seriesfor Edge Intelligence26.6.2025 02:00:00 CEST | Press release
Highly scalable architectureoptimized for computer vision and image workloads with extendable instruction set VeriSilicon (688521.SH) today released the ZSP5000 Digital Signal Processing (DSP) series IPs, which are based on its fifth-generation silicon-proven DSP architecture. This product line adopts a highly scalable and energy-efficient design, and has been deeply optimized for compute-intensive workloads such as computer vision and embedded AI. Combined with the configurable nature of the architecture, this series of IP can provide excellent solutions with both energy and computing efficiency for various edge devices. The ZSP5000 series IPs include ZSP5000, ZSP5000UL, ZSP5000L, and ZSP5000H, delivering scalable vector processing performance ranging from 32 to 256 8-bit Multiply-Accumulate (MAC) operations per cycle. For even higher performance, VeriSilicon’s multi-core ZSP5400H can combine multiple ZSP5000H cores in a multi-cluster architecture to further scale computing capability
Newpark Fluids Systems Strengthens Executive Leadership and Board to Drive Continued Growth25.6.2025 21:39:00 CEST | Press release
Newpark Fluids Systems (“Newpark” or the “Company”), a leading global independent provider of drilling and completion fluids solutions, and SCF Partners (“SCF”) are pleased to announce several key additions to the Company’s executive leadership and Board of Directors. These strategic appointments, along with significant capital investments, including the development of a leading liquid mud facility in West Texas and a new technology center of excellence in Saudi Arabia, underscore Newpark’s commitment to operational excellence, customer value, and accelerated global growth following its acquisition in 2024. Nathan Snoke has joined Newpark Fluids Systems as Senior Vice President, Western Hemisphere bringing nearly two decades of predominantly North American oilfield experience to his role, most recently holding operational and commercial leadership positions with Halliburton and Flotek. He has worked across every major U.S. shale play—from the Rockies and Permian to the Marcellus and Ha
Intelsat Partners with Whitaker Peace & Development Initiative to Expand Access to Education in East Africa25.6.2025 21:00:00 CEST | Press release
Satellite-powered connectivity will support enhanced online education in conflict-affected regions in South Sudan and Uganda Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks, announced today a groundbreaking partnership with Academy Award-winning actor and humanitarian Forest Whitaker’s nonprofit, the Whitaker Peace & Development Initiative (WPDI), to revolutionize access to education in conflict-affected regions across Africa. The collaboration will deliver for the first time high-speed internet connectivity to WPDI’s Community Learning Centers in South Sudan and Uganda, creating digital bridges to education for thousands of young people in areas where infrastructure has been insufficient or compromised. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625237871/en/ This unprecedented effort will bring reliable internet access to communities where traditional connectivity infra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom